Owens & Minor, Inc. Q2 2025 Earnings Recap

OMI Q2 2025 August 11, 2025

Get alerts when OMI reports next quarter

Owens & Minor reported robust growth in its Patient Direct business amid the planned divestiture of its Products & Healthcare Services segment, positioning the company for future profitability in the evolving home-based care market.

Earnings Per Share Miss

$0.26 vs $0.27 est.

-3.7% surprise

Revenue Miss

681917000 vs 2374745500 est.

-71.3% surprise

Market Reaction

1-Day +18.14%

5-Day +17.71%

30-Day +18.14%

See OMI alongside your other holdings

Add to your portfolio — free

Key Takeaways

Projected revenue for the Patient Direct segment is expected to reach between $2.76 billion and $2.82 billion in 2025, with adjusted EBITDA ranging from $376 million to $382 million.
The divestiture process for the Products & Healthcare Services segment is underway, allowing the company to concentrate on the higher-margin, higher-growth Patient Direct business.
Demographic trends underpinning the demand for home-based care are strong, with substantial growth potential driven by increasing chronic health conditions among American adults.
Despite the termination of the Rotech acquisition, management remains focused on selective acquisition opportunities to enhance Patient Direct capabilities.
Initiatives to drive revenue and EBITDA growth include advancements in IT infrastructure, revenue cycle improvements, and an expanded sales force.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit OMI on AllInvestView.